sorafenib has been researched along with pd 0325901 in 14 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (pd 0325901) | Trials (pd 0325901) | Recent Studies (post-2010) (pd 0325901) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 299 | 7 | 256 |
| Protein | Taxonomy | sorafenib (IC50) | pd 0325901 (IC50) |
|---|---|---|---|
| Cytochrome P450 1A2 | Homo sapiens (human) | 0.015 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 0.015 | |
| Serine/threonine-protein kinase B-raf | Homo sapiens (human) | 0.006 | |
| Mitogen-activated protein kinase 1 | Homo sapiens (human) | 0.025 | |
| Dual specificity mitogen-activated protein kinase kinase 1 | Mus musculus (house mouse) | 0.0003 | |
| Dual specificity mitogen-activated protein kinase kinase 2 | Homo sapiens (human) | 0.078 | |
| Dual specificity mitogen-activated protein kinase kinase 1 | Homo sapiens (human) | 0.0285 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 10 (71.43) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Alessi, DR; Arthur, JS; Bain, J; Cohen, P; Elliott, M; Hastie, CJ; Klevernic, I; McLauchlan, H; Plater, L; Shpiro, N | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Jin, H; Liang, L; Niu, Y; Peng, Y; Sun, J; Wang, C; Xie, B; Xu, F; Xu, P; Zhang, H | 1 |
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Bharate, SB; Raghuvanshi, R | 1 |
| Lyons, J; Thompson, N | 1 |
| Clemetson, KJ | 1 |
| Abrams, SL; Andreeff, M; Bergamo, P; Chiaretti, S; Ciuffreda, L; Cognetti, F; Del Bufalo, D; Foà, R; Konopleva, M; Marchetti, A; Mascolo, MG; McCubrey, JA; Milella, M; Petrucci, MT; Ricciardi, MR; Scerpa, MC; Steelman, LS; Tafuri, A; Tavolaro, S; Tsao, T | 1 |
| Bouzin, C; Calderon, PB; Charette, N; Danhier, P; Feron, O; Gallez, B; Grégoire, V; Jordan, BF; Karroum, O; Kengen, J; Magat, J; Mignion, L; Sonveaux, P; Starkel, P; Verrax, J | 1 |
| Andersen, NJ; Baker, LH; Boguslawski, EA; Dawes, MJ; Duesbery, NS; Dykema, KJ; Froman, RE; Furge, KA; Kamstock, DA; Kitchell, BE; Krivochenitser, RI; Nickoloff, BJ; Thomas, DG | 1 |
| Bandyopadhyay, S; Burlingame, AL; Gordan, JD; Hann, B; Levin, RS; McCormick, F; Oses-Prieto, JA; Salt, M; Shokat, KM; Sos, ML; Webber, JT | 1 |
| Wu, CH; Wu, X; Zhang, HW | 1 |
| Bruner, JK; Jones, RJ; Levis, MJ; Li, L; Ma, HS; Pratilas, CA; Pratz, KW; Qin, ACR; Rudek, MA; Small, D | 1 |
| Barney, LE; Hall, CL; Jansen, LE; Meyer, AS; Nguyen, TV; Peyton, SR; Schwartz, AD | 1 |
1 review(s) available for sorafenib and pd 0325901
| Article | Year |
|---|---|
Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery.
Topics: Animals; Benzamides; Benzenesulfonates; Clinical Trials as Topic; Diphenylamine; Extracellular Signal-Regulated MAP Kinases; Humans; Molecular Structure; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Pyridines; Signal Transduction; Sorafenib | 2005 |
13 other study(ies) available for sorafenib and pd 0325901
| Article | Year |
|---|---|
The selectivity of protein kinase inhibitors: a further update.
Topics: Amino Acid Sequence; Animals; Cell Line; Drug Design; Enzyme Activation; Humans; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Recombinant Proteins; Spodoptera | 2007 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Discovery of 3-benzyl-1,3-benzoxazine-2,4-dione analogues as allosteric mitogen-activated kinase kinase (MEK) inhibitors and anti-enterovirus 71 (EV71) agents.
Topics: Allosteric Regulation; Antiviral Agents; Cell Line; Drug Discovery; Enterovirus A, Human; Extracellular Signal-Regulated MAP Kinases; Humans; Protein Kinase Inhibitors | 2016 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases | 2022 |
American Society of Hematology--48th Annual Meeting and Exposition. Updates on therapies. 9-12 December 2006 Orlando, FL, USA.
Topics: Anemia, Sickle Cell; Antibiotics, Antineoplastic; Antigens, CD20; Benzamides; Benzenesulfonates; CD40 Antigens; Diphenylamine; Hematologic Neoplasms; Hematology; Humans; Ki-1 Antigen; Leukemia, Myeloid; Lymphoma; MAP Kinase Kinase Kinases; Niacinamide; Phenylurea Compounds; Pyridines; Sirolimus; Sorafenib | 2007 |
Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Benzenesulfonates; Cell Proliferation; Cell Survival; Diphenylamine; Drug Resistance, Neoplasm; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Inhibitory Concentration 50; Intracellular Signaling Peptides and Proteins; Leukemia, Myeloid, Acute; MAP Kinase Kinase 1; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-raf; Pyridines; Signal Transduction; Sorafenib; Transcriptome; Tumor Cells, Cultured | 2012 |
Tumor reoxygenation following administration of Mitogen-Activated Protein Kinase inhibitors: a rationale for combination with radiation therapy.
Topics: Angiogenesis Inducing Agents; Animals; Apoptosis; Benzamides; Blotting, Western; Diphenylamine; Electron Spin Resonance Spectroscopy; Fibrosarcoma; Glutathione; Liver Neoplasms, Experimental; Mice; Neoplasms, Experimental; Niacinamide; Oxygen Consumption; Phenylurea Compounds; Protein Kinase Inhibitors; Radiation Tolerance; Sorafenib | 2012 |
Pharmacologic inhibition of MEK signaling prevents growth of canine hemangiosarcoma.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Proliferation; Diphenylamine; Disease Models, Animal; Dogs; Drug Screening Assays, Antitumor; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Hemangiosarcoma; Humans; Mice; Mice, Nude; Mitogen-Activated Protein Kinase Kinases; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autocrine Communication; Benzamides; Cell Line, Tumor; Cell Survival; Diphenylamine; Drug Resistance, Neoplasm; Female; Humans; Interleukin-6; MAP Kinase Signaling System; Mice, Nude; Mitogen-Activated Protein Kinases; Mutation, Missense; Niacinamide; Oncogenes; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Sorafenib; Xenograft Model Antitumor Assays | 2014 |
Inhibition of acquired-resistance hepatocellular carcinoma cell growth by combining sorafenib with phosphoinositide 3-kinase and rat sarcoma inhibitor.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diphenylamine; Drug Resistance, Neoplasm; Heterocyclic Compounds, 3-Ring; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2016 |
Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase-Driven Leukemias and Other Malignancies.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Cell Proliferation; Diphenylamine; Female; HL-60 Cells; Humans; K562 Cells; Leukemia, Myeloid, Acute; MAP Kinase Signaling System; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Random Allocation; Sorafenib; Xenograft Model Antitumor Assays | 2017 |
A biomaterial screening approach reveals microenvironmental mechanisms of drug resistance.
Topics: Animals; Antineoplastic Agents; Benzamides; Biocompatible Materials; Cell Communication; Cell Line, Tumor; Diphenylamine; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Extracellular Matrix; Female; Humans; Hydrogels; Hydrogen; Linear Models; MAP Kinase Kinase Kinases; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Phosphoproteins; Phosphorylation; Plastics; Sorafenib; Spheroids, Cellular; Systems Biology; Transcriptome; Tumor Microenvironment | 2017 |